Online inquiry

IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11522MR)

This product GTTS-WQ11522MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets FGFR3 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000142.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2261
UniProt ID P22607
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ11522MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7616MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ11376MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-573
GTTS-WQ9153MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMGN-289
GTTS-WQ13566MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRX-302
GTTS-WQ9596MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ12167MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MORAb-009
GTTS-WQ7389MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ4613MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-986015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW